(19)

(12)





(11) **EP 2 995 951 A1**

G01N 33/543 (2006.01)

C07K 14/58 (2006.01)

EUROPEAN PATENT APPLICATION

(51) Int Cl.:

G01N 33/53 (2006.01)

C07K 14/54 (2006.01)

Jacobson, Sven

New York 10001 (US)

New York

- (43) Date of publication: 16.03.2016 Bulletin 2016/11
- (21) Application number: 15163587.7
- (22) Date of filing: 02.05.2007
- (84) Designated Contracting States:
 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
 HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
 SI SK TR
- (30) Priority: 02.05.2006 US 797285 P
- (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
 07761742.1 / 2 019 965
- (71) Applicant: Critical Care Diagnostics, Inc. New York, New York 10019 (US)
- (72) Inventors:
 Snider, James V.
 Pleasanton
 California 94588 (US)

EP 2 995 951 A1

(74) Representative: Williams, Gareth Owen Marks & Clerk LLP 62-68 Hills Road Cambridge CB2 1LA (GB)

Remarks:

This application was filed on 14-04-2015 as a divisional application to the application mentioned under INID code 62.
Claims filed after the date of filing of the application/after the date of receipt of the divisional application (Rule 68(4) EPC).

(54) METHOD FOR SELECTING TREATMENT BASED ON DIFFERENTIAL DIAGNOSIS BETWEEN PULMONARY AND CARDIOVASCULAR DISEASE

(57) Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2/Interleukin 1 Receptor Like 1 (IL1RL1) and/or Interleukin 33 (IL-33), and a biomarker for CVD, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-Terminal proBNP (NT-proB-NP), atrial natriuretic peptide (ANP), proANP, or NT-proANP.

Figure 1

			210113	2000			
		ST2 not HF Not COPD	ST2 not HF ÇOPD	st2 hot HF	ST2 HF not COPD	ST2 HF COPD	ST2 CHF
N	Valid	224	161	385	155	53	208
	Missing	375	438	214	444	546	391
Median		.1220	.2305	.1448	.4944	.6532	.5033
Percentiles	25	.0502	.0823	,0622	.2393	.2819	.2671
	75	.2232	.6555	,4227	1.1287	1.9560	1.2254
*****			.001	P<0.001	P=0		

Statistics

Printed by Jouve, 75001 PARIS (FR)

Description

TECHNICAL FIELD

⁵ **[0001]** This invention relates to methods for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2 (which is also known as Interleukin 1 Receptor Like 1 (IL1RL1)) and/or Interleukin 33 (IL-33), and a diagnostic biomarker, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP.

10 BACKGROUND

[0002] Non-specific symptoms such as dyspnea and chest pain are a common problem in the outpatient primary care setting. Establishing a diagnosis can be challenging because the differential diagnosis can include multiple diagnostic categories, including cardiovascular and pulmonary diseases. Underlying disorders can range from relatively benign conditions (e.g., hyperventilation) to more serious and even life-threatening diseases (e.g., pulmonary embolism or heart failure), which are best addressed in an emergency department. Timely assessment, accurate diagnosis, and initiation of appropriate therapy play a critical role in optimizing treatment and patient recovery.

SUMMARY

15

20

[0003] The present invention includes methods for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject. The methods use ST2 (IL1RL1) and/or Interleukin-33 (IL-33), in combination with other biomarkers including the natriuretic peptides (NPs).

- [0004] In one aspect, the invention provides methods for determining the likelihood of the presence of a cardiovascular disease or a pulmonary disease in a subject. The methods include optionally obtaining a biological sample from the subject; determining a level of a first biomarker selected from the group consisting of ST2 and/or IL-33 in such a sample; determining a level of a second biomarker for a cardiovascular disease (CVD) in the sample; and comparing the levels of the first and second biomarkers in the sample to reference levels. The levels of the biomarkers in the sample as compared to the reference levels is correlated with (i.e., is statistically correlated with) the likelihood that the subject has
- ³⁰ a pulmonary disease or CVD. In some embodiments, the subject has a non-specific symptom, e.g., dyspnea or chest pain, that suggests a diagnosis of a pulmonary disease or CVD, and the biomarker levels indicate which of the two diseases, if any, the subject has.

[0005] The CVD biomarker is a biomarker that is diagnostic of a cardiovascular condition. In some embodiments, the CVD biomarker is a natriuretic peptide (NP), e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP. In some embodiments, the CVD biomarker

is BNP.

35

55

[0006] In some embodiments of the methods described herein, the biological sample comprises blood, serum, plasma, urine, or body tissue. In some embodiments, the sample is a serum sample.

[0007] In some embodiments of the methods described herein, the reference levels represent levels in a subject who does not have a CVD or a PD. In some embodiments, the reference levels represent levels in a subject who has a CVD. In some embodiments, the reference levels represent levels in a subject who has a PD, or both a PD and a CVD.

[0008] Determining a level of a biomarker in the sample can include contacting a binding composition to the sample, wherein the binding composition specifically binds to the biomarker, and measuring or determining the specific binding of the binding composition to the sample. Suitable binding compositions include antibodies that bind specifically to a biomarker polypeptide and oligonucleotide probes that bind specifically to a polynucleotide encoding a biomarker.

- [0009] In some embodiments, the subject has dyspnea and the CVD diagnosed by a method described herein is congestive heart failure, coronary artery disease (CAD), arrhythmia, pericarditis, acute myocardial infarction, or anemia.
 [0010] In some embodiments, the subject has dyspnea and the pulmonary disease diagnosed by methods described herein is chronic obstructive pulmonary disease (COPD), asthma, pneumonia, pneumothorax, pulmonary embolism, pleural effusion, metastatic disease, pulmonary edema, gastrooesophageal reflux disease with aspiration, or restrictive
- ⁵⁰ pleural effusion, metastatic disease, pulmonary edema, gastrooesophageal reflux disease with aspiration, or restrictive lung disease. **100111** In some embodiments, the methods described herein also include determining a level in the sample of one or

[0011] In some embodiments, the methods described herein also include determining a level in the sample of one or more other additional biomarkers, e.g., biomarkers selected from the group consisting of troponin, myoglobin, creatine kinase MB (CK-MB), ischemia-modified albumin (IMA), Interleukin-6 (IL-6), C-reactive protein (CRP), creatinine, D-dimers, blood urea nitrogen (BUN), liver function enzymes, albumin, and bacterial endotoxin.

[0012] In an additional aspect, the invention features kits for diagnosing pulmonary diseases. The kits include one or more separate antibodies that each specifically bind to a biomarker used in the methods described herein, and/or an oligonucleotide probe that specifically binds to a nucleic acid encoding said biomarkers, and instructions for use in a

method described herein.

[0013] Also described herein are kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject. The kits include (i) one or both of a binding composition that specifically binds to IL-33 and a binding composition that specifically binds to ST2, (ii) a binding composition binds to a biomarker for CVD,

- ⁵ and (iii) instructions for use in a method of determining the likelihood of the presence of CVD or PD in a subject described herein. In some embodiments, the IL-33 and/or ST2 and the CVD biomarker comprise polypeptides, and the binding composition includes an antibody or antigen binding fragment thereof that binds specifically to each of the polypeptides. In some embodiments, the IL-33 and/or ST2 and the CVD biomarker comprises a nucleic acid or a nucleic acid probe that binds specifically to each of the nucleic acids.
- ¹⁰ **[0014]** A "cardiovascular disease," as used herein, refers to a disorder of the heart and blood vessels, and includes disorders of the arteries, veins, arterioles, venules, and capillaries. Cardiovascular diseases diagnosed by a method described herein can include congestive heart failure (HF), coronary artery disease (CAD), arrhythmia, pericarditis, and acute myocardial infarction (MI).
- [0015] A "pulmonary disease," as used herein, refers to a disorder of the lungs. Pulmonary diseases diagnosed by methods described herein can include chronic obstructive pulmonary disease (COPD), asthma, pneumonia, pneumothorax, pulmonary embolism, pleural effusion, metastatic disease, pulmonary edema, gastrooesophageal reflux disease with aspiration, and/or restrictive lung disease.

[0016] "Upregulated," as used herein, refers to increased expression of a gene and/or its encoded polypeptide. "Increased expression" refers to increasing (i.e., to a detectable extent) replication, transcription, and/or translation of a

- 20 gene, e.g., ST2, since upregulation of any of these processes results in an increase in concentration/amount of the polypeptide encoded by the gene. Conversely, "downregulation," or "decreased expression" as used herein, refers to reduced replication, transcription, and/or translation of the gene and/or its encoded polypeptide. The upregulation or downregulation of gene expression can be directly determined by detecting an increase or decrease, respectively, in the level of mRNA for the gene, or the level of protein expression of the gene-encoded polypeptide, using any suitable
- ²⁵ means known to the art, such as nucleic acid hybridization or antibody detection methods, respectively, and in comparison to controls. "Expression," as used herein, refers to nucleic acid and/or polypeptide expression.
 [0017] As used herein, a "subject" is a mammal, e.g., a human or non-human mammal. In general, human nucleic acids and polypeptides, or nucleic acid molecules or polypeptides synthesized or generated to have sequences based on a corresponding human nucleic acid or polypeptide sequence, are preferred for use in diagnosing human subjects.
- [0018] As used herein, a "sample" includes one or more of blood, serum, plasma, urine, and body tissue. In some embodiments, a sample is a serum or blood sample.
 [0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials,
- ³⁵ methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

[0020] Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.

40

DESCRIPTION OF DRAWINGS

[0021]

FIG. 1 is a table illustrating the effect of COPD history on ST2 concentrations in subjects with/without acute HF.
 FIG. 2 is a box graph illustrating levels of ST2 in subjects with COPD/Asthma and/or HF.

DETAILED DESCRIPTION

⁵⁰ **[0022]** Accurate diagnosis of subjects presenting with non-specific symptoms can be difficult, as the symptoms can have very different etiology. For example, subjects with dyspnea (shortness of breath, or uncomfortable breathing) may be suffering from a pulmonary disease or a cardiovascular disease, both, or neither.

General Methodology

55

[0023] In general, the methods described herein include evaluating levels of a first biomarker (ST2 and/or IL-33) and a second, CVD biomarker (e.g., a natriuretic peptide (NP)) in a biological sample (e.g., a blood, serum, plasma, urine, or body tissue sample) from a subject, e.g., a mammal, e.g., a human. These levels can provide diagnostic information,

e.g., indicating whether the subject has a pulmonary disease (PD) or a cardiovascular disease (CVD), as described herein. In some embodiments, the second biomarker is a NP selected from the group consisting of brain natriuretic peptide (BNP), proBNP, NT-proBNP, atrial natriuretic peptide (ANP), proANP, or NT-proANP.

[0024] In one example, diagnosis of CVD versus PD can be made by referring to Table 1.

5

		Low ST2 (e.g., < 0.20 ng/mL serum)	High ST2 (e.g., \geq 0.20 ng/mL serum)
	Low BNP (< 100 pg/mL)	low probability of either CVD or PD	probable PD
10	Moderate BNP (100-500 pg/ml)	possible CVD	possible PD
	High BNP (> 500 pg/ml)	probable CVD	highly probable CVD

Table 1: Diagnosis of CVD vs PD

[0025] Thus, for a subject who has both low levels of a CVD biomarker, e.g., BNP, and low levels of ST2, there is a low probability of the presence of either CVD or PD. Low levels of the CVD biomarker and high levels of ST2 indicate a greater likelihood of PD than CVD.

[0026] For a subject who has moderate levels of BNP, low levels of ST2 indicate that the presence of CVD is possible (and more likely than PD), while high levels of ST2 indicate that the presence of PD is possible (and more likely than CVD). [0027] Finally, for a subject who has high levels of a CVD biomarker, low levels of ST2 indicate that CVD is probable (and more likely than PD) and high levels of a CVD biomarker, low levels of ST2 indicate that CVD is probable (and more likely than PD).

(and more likely than PD), and high levels of ST2 indicate that CVD is highly probable (and more likely than PD). [0028] Using the methods described herein, diagnoses can be ruled in or ruled out for a given subject, allowing a care giver to focus diagnostic efforts, and thus therapeutic efforts, appropriately. Although it is possible that both etiologies may exist simultaneously in a subject, at any given point in time (and particularly in an acute care situation such as presentation with dyspnea) it is likely one etiology would be more "dominant" than the other, and thus would be the primery terrent for the terrent for the terrent for the terrent.

²⁵ primary target for treatment.

[0029] In some embodiments, the levels of the biomarkers are determined once, e.g., at presentation. In some embodiments, the levels of the biomarkers are determined at any one or more of 1, 2, 3, 4, 5, 6, 7, 8, 12, 18, and/or 24 hours, and/or at 1-7 days or longer, after the onset of symptoms.

- [0030] In embodiments where the levels of the biomarkers are determined more than once, the highest level or an average can be used, or the change in levels can be determined and used. Levels of the biomarkers can also be determined multiple times to evaluate a subject's response to a treatment. For example, levels, e.g., of IL-33 and/or ST2, that are taken after administration of a treatment, e.g., one or more doses or rounds of a treatment, can be compared to levels taken before the treatment was initiated, e.g., baseline levels. The change in levels would indicate whether the treatment was effective; e.g., a reduction in levels would indicate that the treatment was effective.
- ³⁵ **[0031]** Evaluating levels of the biomarker in a subject typically includes obtaining a biological sample, e.g., serum or blood, from the subject. Levels of the biomarkers in the sample can be determined by measuring levels of biomarker polypeptides in the sample, using methods known in the art and/or described herein, e.g., immunoassays such as enzyme-linked immunosorbent assays (ELISA). Alternatively, levels of mRNA encoding the biomarkers can be measured, again using methods known in the art and/or described herein, e.g., by quantitative PCR or Northern blotting analysis.
- ⁴⁰ [0032] For example, a method as described herein, e.g., for differential diagnosis of pulmonary disease, can include contacting a sample from a subject, e.g., a sample including blood, serum, plasma, urine, or body tissue from the subject, with a binding composition (e.g., an antibody or oligonucleotide probe) that specifically binds to a polypeptide or nucleic acid of the biomarkers as described herein. The methods can also include contacting a sample from a control subject, normal subject, or normal tissue or fluid from the test subject, with the binding composition, e.g., to provide a reference
- ⁴⁵ or control. Moreover, the method can additionally include comparing the specific binding of the composition to the test subject with the specific binding of the composition to the normal subject, control subject, or normal tissue or fluid from the test subject. Expression or activity of biomarkers in a test sample or test subject can also be compared with that in a control sample or control subject. A control sample can include, e.g., a sample from a non-affected subject, or a subject who has a known condition, e.g., a pulmonary disease or a cardiovascular disease. Expression or activity from a control
- ⁵⁰ subject or control sample can be provided as a predetermined value, e.g., acquired from a statistically appropriate group of control subjects.

[0033] An antibody that "binds specifically to" an antigen, binds preferentially to the antigen in a sample containing other proteins. The term "antibody" as used herein refers to an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. Examples of immunologically active portions of immunoglobulin molecules

⁵⁵ include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The antibody can be polyclonal, monoclonal, recombinant, e.g., a chimeric or humanized, fully human, non-human, e.g., murine, monospecific, or single chain antibody. In some embodiments it has effector function and can fix complement.

[0034] An "oligonucleotide probe" (also referred to simply as a "probe") is a nucleic acid that is at least 10, and less than 200 (typically less than about 100 or 50) base pairs in length. A probe that "binds specifically to" a target nucleic acid hybridizes to the target under high stringency conditions. As used herein, the term "hybridizes under high stringency conditions" describes conditions for hybridization and washing. As used herein, high stringency conditions are 0.5 M

sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C. Methods for performing nucleic acid hybridization assays are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
 [0035] Detection can be facilitated by coupling (i.e., physically linking) the antibody or probe to a detectable substance

(i.e., antibody labeling). Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes

- ¹⁰ materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, quantum dots, or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent
- ¹⁵ materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

[0036] Diagnostic assays can be used with biological matrices such as live cells, cell extracts, cell lysates, fixed cells, cell cultures, bodily fluids, or forensic samples. Conjugated antibodies useful for diagnostic or kit purposes, include antibodies coupled to dyes, isotopes, enzymes, and metals, see, e.g., Le Doussal et al., New Engl. J. Med. 146:169-175

(1991); Gibellini et al., J. Immunol. 160:3891-3898 (1998); Hsing and Bishop, New Engl. J. Med. 162:2804-2811 (1999); Everts et al., New Engl. J. Med. 168:883-889 (2002). Various assay formats exist, such as radioimmunoassays (RIA), ELISA, and lab on a chip (U.S. Pat. Nos. 6,176,962 and 6,517,234).

[0037] Known techniques in biochemistry and molecular biology can be used in the methods described herein (see, e.g., Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,

²⁵ N.Y. (1982); Sambrook and Russell, Molecular Cloning, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001); Wu, Recombinant DNA, Vol. 217, Academic Press, San Diego, Calif (1993); and Ausbel et al., Current Protocols in Molecular Biology, Vols. 1-4, John Wiley and Sons, Inc. New York, N.Y. (2001)).
 [0038] Once a level of a biomarker has been determined, the level can be compared to a reference level. In some

and the reference level will represent a threshold level, above which the subject can be diagnosed with CVD
 or PD disease. The reference level chosen may depend on the methodology used to measure the levels of the biomarkers.
 In some embodiments, the reference level is a range of levels.

[0039] In some embodiments, both levels of ST2 and IL-33 are determined, and the information from the comparison of both biomarkers with their respective reference levels provides cumulative information regarding the presence of pulmonary disease in the subject, and/or the presence of a severe disease in the subject. In some embodiments, the ratio of ST2 to IL-33 may be determined, and the ratio compared to a reference ratio that represents a threshold ratio

³⁵ ratio of ST2 to IL-33 may be determined, and the ratio compared to a reference ratio that represe above which the subject has CVD or PD, e.g., as shown in Table 1.

ST2/Interleukin 1 Receptor-Like 1 (IL1RL1)

- 40 [0040] The ST2 gene is a member of the interleukin-1 receptor family, whose protein product exists both as a transmembrane form, as well as a soluble receptor that is detectable in serum (Kieser et al., FEBS Lett. 372(2-3):189-93 (1995); Kumar et al., J. Biol. Chem. 270(46):27905-13 (1995); Yanagisawa et al., FEBS Lett. 302(1):51-3 (1992); Kuroiwa et al., Hybridoma 19(2):151-9 (2000)). ST2 was recently described to be markedly up-regulated in an experimental model of heart failure (Weinberg et al., Circulation 106(23):2961-6 (2002)), and preliminary results suggest that ST2 concentration.
- trations may be elevated in those with chronic severe HF (Weinberg et al., Circulation 107(5):721-6 (2003)) as well as in those with acute myocardial infarction (MI) (Shimpo et al., Circulation 109(18):2186-90 (2004)).
 [0041] The transmembrane form of ST2 is thought to play a role in modulating responses of T helper type 2 cells (Lohning et al., Proc. Natl. Acad. Sci. U. S. A. 95(12):6930-5 (1998); Schmitz et al., Immunity 23(5):479-90 (2005)), and may play a role in development of tolerance in states of severe or chronic inflammation (Brint et al., Nat. Immunol.)
- 50 5(4):373-9 (2004)), while the soluble form of ST2 is up-regulated in growth stimulated fibroblasts (Yanagisawa et al., 1992, supra). Experimental data suggest that the ST2 gene is markedly up-regulated in states of myocyte stretch (Weinberg et al., 2002, supra) in a manner analogous to the induction of the BNP gene (Bruneau et al., Cardiovasc. Res. 28(10):1519-25 (1994)).
- [0042] Tominaga, FEBS Lett. 258:301-304 (1989), isolated murine genes that were specifically expressed by growth stimulation in BALB/c-3T3 cells; they termed one of these genes St2 (for Growth <u>Sti</u>mulation-Expressed Gene 2). The St2 gene encodes two protein products: ST2 (IL1RL1), which is a soluble secreted form; and ST2L, a transmembrane receptor form that is very similar to the interleukin-1 receptors. The HUGO Nomenclature Committee designated the human homolog, the cloning of which was described in Tominaga et al., Biochim. Biophys. Acta. 1171:215-218 (1992),

as Interleukin 1 Receptor-Like 1 (IL1RL1). The two terms (ST2 and IL1RL1) are used interchangeably herein. [0043] The mRNA sequence of the shorter, soluble isoform of human ST2 can be found at GenBank Acc. No. NM_003856.2, and the polypeptide sequence is at GenBank Acc. No. NP_003847.2; the mRNA sequence for the longer form of human ST2 is at GenBank Acc. No. NM_016232.4; the polypeptide sequence is at GenBank Acc. No.

- ⁵ NP_057316.3. Additional information is available in the public databases at GeneID: 9173, MIM ID # 601203, and UniGene No. Hs.66. In general, in the methods described herein, the soluble form of ST2 polypeptide is measured. [0044] Methods for detecting and measuring ST2 are known in the art, e.g., as described in U.S. Pat. Pub. Nos. 2003/0124624, 2004/0048286 and 2005/0130136, the entire contents of which are incorporated herein by reference. Kits for measuring ST2 polypeptide are also commercially available, e.g., the ST2 ELISA Kit manufactured by Medical
- & Biological Laboratories Co., Ltd. (MBL International Corp., Woburn, MA), no. 7638. In addition, devices for measuring ST2 and other biomarkers are described in U.S. Pat. Pub. No. 2005/0250156.
 [0045] In some embodiments, the level of ST2 is determined once, e.g., at presentation. In some embodiments, the level of ST2 is determined at one or more of 2, 4, 6, 8, 12, 18, and/or 24 hours, and/or 1-7 days after the onset of symptoms.
 [0046] In some embodiments, the level of ST2 is determined more than once; in that case, the higher measurement
- ¹⁵ can be used. In embodiments, the level of ST2 is determined more that once, in that case, the higher measurement ¹⁵ can be used. In embodiments where the level of ST2 is determined more that once, the highest level can be used, or the change in levels can be determined and used. Levels of ST2 can also be determined multiple times to evaluate a subject's response to a treatment. For example, a level of ST2 taken after administration of a treatment, e.g., one or more doses or rounds of a treatment, can be compared to levels of ST2 before the treatment was initiated, e.g., a baseline level. The change in ST2 levels would indicate whether the treatment was effective; e.g., a reduction in ST2 levels would
- indicate that the treatment was effective.
 [0047] In some embodiments, the methods include determining the identity of the nucleotide sequence at RefSNP ID: rs1041973.

Interleukin-33 (IL-33)

25

30

[0048] IL-33 was recently identified as the ligand for ST2, and the presence of increased levels of IL-33 in various inflammatory disorders has been described (see

[0049] Schmitz et al., Immunity 23(5):479-90 (2005); U.S. Pat. Pub. No. 2005/0203046). In the methods described herein, ST2 can be measured in addition to IL-33. The ratio of ST2 to IL-33 can also be determined, as can ratios of bound complexes to bound and/.

[0050] IL-33 protein is expressed as an inactive molecule, pre-IL-33, that is activated after cleavage by Caspase I resulting in the active IL-33 peptide as well as the cleavage peptide product, pro-IL-33. Therefore, the methods described herein can include measuring one, two, or all three of mature IL-33, pre-IL-33, and/or pro-IL-33, all of which are included in the term "IL-33."

- ³⁵ [0051] The nucleic acid sequence of IL-33 can be found at GenBank Acc. No. NM_033439.2, and the polypeptide sequence is at GenBank Acc. No. NP_254274.1. Additional information is available in the public databases at GeneID: 90865, MIM ID # *608678, and UniGene No. Hs.348390. IL-33 is also known as Chromosome 9 Open Reading Frame 26 (C9ORF26); Nuclear Factor from High Endothelial Venules (NFHEV); and Interleukin 33. See also Baekkevold et al., Am. J. Path. 163: 69-79 (2003).
- ⁴⁰ **[0052]** Methods for measuring levels of IL-33 polypeptide and nucleic acid are known in the art, see, e.g., Schmitz et al., Immunity 23(5):479-90 (2005); U.S. Pat. Pub. No. 2005/0203046.

CVD Biomarkers

- ⁴⁵ [0053] The methods described herein include measuring levels of CVD biomarkers in addition to IL1RL1 (ST2) and/or IL-33. Suitable biomarkers for CVD include troponin, NT-proBNP, BNP, NT-proANP, and ANP.
 [0054] In some embodiments, the CVD diagnostic biomarker is B-type natriuretic peptide (BNP), a marker of hemo-
- dynamic stress characteristic of heart failure. Levels of BNP can be determined, e.g., in whole blood or serum, using standard methodology. For example, a number of assay kits are commercially available, e.g., the Triage BNP Test
 (Biosite, Inc., San Diego, CA), a point-of-care assay that whole blood or plasma and produces results in about 15 minutes; a chemiluminescent sandwich immunoassay (Bayer HealthCare Diagnostics, Tarrytown, NY) for BNP that is run on the ADVIA Centaur and ACS:180 platform; and a chemiluminescent immunoassay (Abbott Laboratories, Abbott Park, IL) for BNP that is run on the ADVIA that is run on the ADVIA Centaur and ACS:180 platform; and a chemiluminescent immuno assay (Rissite, Inc., San Diago, CA), a platform; and a chemiluminescent immunoassay (Abbott Laboratories, Abbott Park, IL) for BNP that is run on the ADVIA Centaur and ACS:180 platform; and a chemiluminescent immuno assay (Biostic, Inc., San Diago, CA), a platform; and a chemiluminescent immunoassay (Abbott Laboratories, Abbott Park, IL) for BNP that is run on the ADVIA Centaur and ACS:180 platform; and a chemiluminescent immunoassay (Abbott Laboratories, Abbott Park, IL) for BNP that is run on the ADVIA centaur and ACS:180 platform; and a chemiluminescent immuno and the ASSAM platform; and a chemiluminescent immuno assay (Biostic, Inc., San Diago, CA), a platform; and a chemiluminescent immuno assay (Abbott Laboratories, Abbott Park, IL) for BNP that is run on the ADVIA Centaur and ACS:180 platform; and a chemiluminescent immuno assay (Biostic, Inc., San Diago, CA), a platform; and a chemiluminescent immuno assay (Biostic, Inc., San Diago, CA), a platform; and a chemiluminescent immuno assay (Biostic, Inc., San Diago, CA), a platform; and a chemiluminescent immuno assay (Biostic, Inc., San Diago, CA), a platform; and a chemiluminescent immuno assay (Biostic, Inc., San Diago, CA), a platform; and a chemiluminescent immuno assay (Biostic, Inc., San Diago, CA), a platform; and a chemiluminescent immuno ass
- BNP that is run on the AxSYM platform; and a chemiluminescent immuno-enzymatic assay (Biosite, Inc., San Diego, CA) for BNP that is run on the following Beckman Coulter platforms: Access, Access 2, Synchron LXI and the UniCel
 DXI. An electrochemiluminescent assay (Roche Diagnostics, Indianapolis, IN) available for measuring NT-proBNP.
 100551 The reference ranges for BNP and NTproBNP vary depending on a number of factors. The following ranges
- **[0055]** The reference ranges for BNP and NTproBNP vary depending on a number of factors. The following ranges are for use where BNP levels are measured using an ELISA-type method, and one of skill in the art will be able to determine what levels obtained using other methods are equivalent. If the BNP level is >500 pg/mL, then HF is highly

likely. Levels of BNP of 100-500 pg/mL are often described as a "grey zone," in which diagnosis is less certain. In lean subjects, if the BNP is <100 pg/mL, then HF is unlikely, however, obesity influences the expression of BNP in chronic HF (Mehra et al., J Am Coll Cardiol. 43(9):1590-1595 (2004)), so levels of < 100 pg/mL do not rule out heart failure in obese subjects (Silver et al., Cong. Heart Fail. 10(5 suppl. 3):1-30 (2004)).

5

10

Other Biomarkers

[0056] In some embodiments, the methods also include measuring levels of other biomarkers, e.g., one or more of: troponin, creatine kinase MB (CK-MB), Myoglobin (Myo), ischemia-modified albumin (IMA), Interleukin-6 (IL-6), C-reactive protein (CRP), creatinine, D-dimers, blood urea nitrogen (BUN), liver function enzymes, albumin, and/or bacterial endotoxin. Methods for measuring these biomarkers are known in the art, see, e.g., U.S. Pat. Pub. Nos. 2004/0048286 and 2005/0130136 to Lee et al.; Dhalla et al., Mol. Cell Biochem. 87:85-92 (1989); Moe et al., Am. Heart J. 139:587-95 (2000), the entire contents of which are incorporated herein by reference.

15 Kits

[0057] Also included herein are kits that include a reagent comprising a binding composition for the detection of one or more of the IL-33 or ST2 polypeptide(s) or nucleic acid, e.g., an anti-IL-33 or ST2 antibody (i.e., an antibody or antigen binding fragment thereof that binds specifically to IL-33 or ST2), or a nucleic acid probe complementary to all or part of

20 the IL-33 or ST2 nucleic acid), as well as a reagent comprising a binding composition for the detection of one or more of a CVD biomarker, e.g., a CVD biomarker polypeptide or a nucleic acid encoding a CVD biomarker, and instructions for use in a method described herein. A control can also be included, e.g., an epitope of IL-33 or ST2, and of the CVD biomarker.

[0058] Kits are generally comprised of the following major elements: packaging, reagents comprising binding compo-

- sitions as described above, optionally a control, and instructions. Packaging may be a box-like structure for holding a vial (or number of vials) containing said binding compositions, a vial (or number of vials) containing a control, and instructions for use in a method described herein. Individuals skilled in the art can readily modify the packaging to suit individual needs.
- [0059] As one example, the kit may contain an antibody or antigen binding fragment thereof that binds specifically to ST2 (or IL-33), and an antibody or antigen binding fragment thereof that binds specifically to a CVD biomarker, e.g., BNP, proBNP, NT-proBNP, ANP, proANP, or NT-proANP.
 [0060] In some embodiments, other methods of detection can be used, e.g., colorimetric assays, radioimmunoassays, or chemiluminescent assays. Sandwich assays can be used as well, e.g., using two monoclonal antibodies, one labelled
- with iodine 125 and the other adsorbed onto beads, e.g., as used in the IRMA-BNP2 kit from CISBIO International (France) and the ShionoRIA BNP or ANP kits (SHIONOGI USA Inc.).
 [0061] For example, the kit can be designed for use in a assay is a chemiluminescent microparticle immunoassay (CMIA), such as the ARCHITECT assays from Abbot Diagnostics (Abbott Park, IL), and thus can contain paramagnetic
- microparticles coated with anti-BNP antibodies, and paramagnetic microparticles coated with anti-ST2 antibodies. These microparticles are contacted with a sample, and the BNP and ST2 present in the sample bind to the coated microparticles. Optionally, the sample can be split into at least two aliquots, and each type of microparticle can be contacted with a separate aliquot. After washing, anti-BNP and anti-ST2 acridinium-labeled conjugate can be added to create a reaction mixture in the second step. Following another wash cycle pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured, e.g., using the ARCHITECT i System optics (Abbot Diagnostics, Abbott Park, Illinois). A direct relationship exists between the amount of BNP or ST2 in the sample and the
- ⁴⁵ chemiluminescence detected.

EXAMPLES

[0062] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

Example 1: Detection and Measurement of ST2 in the Serum

[0063] This example uses the ST2 ELISA Kit manufactured by Medical & Biological Laboratories Co., Ltd. (MBL International Corp., Woburn, MA), no. 7638. This kit is a sandwich ELISA assay utilizing monoclonal antibodies for both capture and detection. This procedure is intended to analyze a full plate of samples assayed in replicates at a 1:3 dilution factor and closely follows the manufacturers' protocol. Kits should be stored at 4°C until use. The procedure described in this example is optimized for human serum or plasma collected in citrate or EDTA anticoagulant tubes. Plasma

collected in heparin anticoagulant tubes should not be used in this assay as heparin binds ST2 and inhibits measurement by this ELISA protocol. Plasma or serum samples may be used fresh or stored frozen. This assay is not adversely affected by up to 3 freeze and thaw cycles of plasma samples.

[0064] Reagents should be prepared fresh from a new kit immediately before performing the assays. Allow the kit to equilibrate to room temperature prior to use. Reagents not explicitly discussed below are provided by the manufacturer ready to use.

1. Wash solution - wash solution is provided by the manufacturer as a 10X concentrate solution. To make 1 liter of wash solution dilute 100 ml of the 10X concentrate provided with 900 ml of distilled water.

- 2. Detector solution the detector solution is prepared by diluting the detector concentrate 1:101 with the detector diluent. For a full 96 well plate of samples 10 ml of detector solution is required. To prepare 10 ml of detector solution use a pipette to transfer 10 ml of the blue colored detector diluent to a 15 ml orange top polypropylene tube. Ad 100 μl of the detector concentrate to this volume of detector diluent.
- a. NOTE: this reagent should be prepared during the first assay incubation step.

3. Calibrator stock - reconstitute the calibrator protein by dissolving the lyophilized protein in the amount of distilled water defined by the manufacturer for this manufacturing lot to yield a stock solution of 8 ng/ml. This volume specification is included in the product insert.

20

Preparation of standards and samples:

[0065]

• All of the following should be prepared in labeled 1.5 ml polypropylene tubes to be transferred to the assay plate with the P200 pipetter.

Standards:

- ³⁰ [0066] The standard curve is prepared by making 2 fold serial dilutions of the 8 ng/ml stock solution.
 - 1. Using a P1000 pipette transfer 250 µl of Assay Diluent to 8 1.5 ml polypropylene tubes labeled S1-S8

2. Using the same P1000 pipette transfer 250 μ l of the 8 ng/ml Calibrator stock solution to tube S1. This tube is now 4 ng/ml calibrator protein.

35

50

a. Mix thoroughly by gently pipetting 3 times being careful not to create bubbles.

3. Using the same P1000 pipette and a fresh tip for each of the following transfer 250 μ l of the reagent in tube S1 to tube S2, repeat the mixing.

- 40 4. Repeat step 3 for S2 to S3, S3 to S4, S4 to S5, S5 to S6 and S6 to S7. S8 will be the reagent blank so do not transfer the calibrant protein to this well.
 - a. Tubes S1-S6 and S8 will now have 250 μl of reagent and tube S7 will have 450 μl

45 Samples:

- [0067] The plate is set up so that each sample is analyzed as a 1:3 dilution in duplicate.
 - 1. Label a 1.5 ml polypropylene tube for each sample.
 - 2. Using the P200 pipette transfer 160 μ l of Assay Diluent to each tube.

3. Using a P200 pipette transfer 80 μ l of serum or plasma from sample 1 to tube 1. Mix carefully by pipetting 3 times without making bubbles.

4. Continue transferring samples to the sample tubes by repeating step 2 for each sample.

55 Procedure:

[0068] 1. Use the P200 pipette transfer the standards and diluted serum samples quickly to the 96 well assay plate. An exemplary layout is shown below in Table 2.

- a. Set the P200 pipette for 100 μI
- b. Transfer 100 μ l of the standard curve dilutions to each of columns 1 & 2 in the assay plate

c. Transfer 100 μ l of each of the serum samples to the assay plate in exactly the same positions as shown in the plate map below.

5

- 2. Cover the assay plate with the provided shield and incubate at room temperature for 60 minutes.
- 3. Using the plate autowasher wash the plate 4 times.

4. Detector: using the 8 channel multichannel pipette transfer 100 μ l of the detector solution to each well and incubate at room temperature for 60 minutes.

10

a. NOTE: this reagent was to be prepared during the first incubation step.

b. NOTE: use a disposable reagent vessel for this reagent addition. ALWAYS use a fresh disposable reagent vessel for each reagent. It is not necessary to change pipette tips during this step.

¹⁵ 5. Wash the plate as in step 3

6. Substrate: using the 8 channel multichannel pipette transfer 100 μ l of the Substrate to each well and incubate at room temperature for 30 minutes.

- a. The Substrate reagent is provided ready to use by the manufacturer.
- 20

7. Stop: at the completion of the Substrate incubation using the 8 channel multichannel pipette transfer 100 μ l of the

Stop solution to each well.

a. The Stop Solution reagent is provided ready to use by the manufacturer.

25

8. Read the plate at 450 nm with background correction at 620 nm.

a. The plate should be read within 30 minutes after stopping the reaction.

³⁰ 9. Enter the absorbance readings in the provided spreadsheet for analysis.

Table 2: Map of Exemplary 96 Well Assay Plate												
	1	2	3	4	5	6	7	8	9	10	11	12
А	4.0		1	1	9	9	17	17	25	25	33	33
В	2.0		2	2	10	10	18	18	26	26	34	34
С	1.0		3	3	11	11	19	19	27	27	35	35
D	0.5		4	4	12	12	20	20	28	28	36	36
Е	0.25		5	5	13	13	21	21	29	29	37	37
F	0.125		6	6	14	14	22	22	30	30	38	38
G	0.0625		7	7	15	15	23	23	31	31	39	39
Н	0.0		8	8	16	16	24	24	32	32	40	40

Table 2: Map of Exemplary 96 Well Assay Plate

45

40

35

Example 2: Detection and Measurement of IL-33 in the Serum

[0069] A blood sample is collected from a subject, and serum is prepared from the sample using standard methods. A labeled monoclonal antibody to IL-33 (e.g., as described U.S. Pat. App. Pub. No. 2005/0203046, incorporated herein by reference in its entirety) is added to the sample and incubated for a sufficient amount of time for binding to occur. The antibody/IL-33 complexes are then detected using standard methods, and the amount of IL-33 present is quantified. Levels of IL-33 are expected to correlate with disease in a manner similar to that of ST2, as described herein.

⁵⁵ Example 3: COPD and ST2 Concentrations

[0070] The effect of COPD history on ST2 concentrations in subjects with/without acute HF was evaluated in subjects

from the PRIDE study.

[0071] 600 breathless subjects were enrolled in the PRIDE study, to analyze the utility of NT-proBNP for diagnosis and prognosis of acute heart failure (HF). At enrollment, a blinded sample of blood was obtained, processed and frozen at -80°C. For the purposes of ST2 analysis, an aliquot of citrated blood was thawed (second freeze-thaw cycle) and analyzed for concentration of ST2 protein as described in Example 1.

[0072] The results are shown in Figures 1-2, and demonstrate that elevated ST2 levels, e.g., above 0.2 ng/ml of serum when determined as described in Example 1, can be used to predict the likelihood of the presence of pulmonary disease, e.g., in subjects without acute decompensated heart failure, e.g., with low or moderate BNP levels.

10 Example 4: Elevated ST2 Concentrations in Patients Without Heart Failure

[0073] ST2 concentrations were determined as described in Example 1, above, in a population of 350 patients who presented to the ED with chest pain. Serum samples were obtained and ST2 measurements made at baseline, and 90 and 180 minutes later for most patients. Also for most patients, the baseline sample was collected within 2 hours of

15 onset of symptoms.

5

[0074] 17 patients had final diagnosis of MI, and 5 of these had $ST2 \ge 0.23$ (0.25 - 0.65). Two of these patients were troponin negative. 11 patients had very high ST2 levels (0.97 - 9.22), but none of these patients had confirmed final diagnosis of MI and were all troponin negative, though all had severe diseases, including COPD, lymphoma, sepsis, alcohol abuse, and pulmonary embolism. The ST2 levels and diagnoses for these 11 patients are shown in Table 3;

20 ST2 1 is the baseline level, ST2 2 is 90 minutes later, and ST2 3 is at 180 minutes.

				-
Patient	ST2 1 (baseline) (ng/ml)	ST2 2 (90 mins) (ng/ml)	ST2 3 (180 Mins) (ng/ml)	Final Diagnosis
811	1.43	1.62	1.63	COPD with heart failure following coronary artery bypass graft surgery and pulmonary hypertension
847	2.37	4.44	3.53	Pulmonary embolism
873	2.36	2.42	2.74	Reactive airway disease (RAD)
898	1.32	1.24	1.66	History of heart failure following coronary artery bypass surgery
920	6.03	9.22		Bacteremia sepsis
928	3.80	4.69	3.99	Hypertension and alcohol abuse
952	6.76			Alcohol abuse, gastritis and pulmonary hypertension
953	3.77			History of heart failure following coronary artery by pass surgery
1055	1.42	1.28	1.13	Upper respiratory infection (URI)
1213	0.97	1.19	1.07	Pulmonary embolism and pericarditis
1245	4.11	6.46		Lymphoma and hypertension
1280	1.30	1.33		COPD
	811 847 873 898 920 928 952 953 1055 1213 1245	Patient (ng/ml) 811 1.43 847 2.37 873 2.36 898 1.32 920 6.03 928 3.80 952 6.76 953 3.77 1055 1.42 1213 0.97 1245 4.11	Patient S121 (baseline) (ng/ml) mins) (ng/ml) 811 1.43 1.62 847 2.37 4.44 873 2.36 2.42 898 1.32 1.24 920 6.03 9.22 928 3.80 4.69 952 6.76	PatientS12 1 (baseline) (ng/ml)mins) (ng/ml)S12 3 (180 Mins) (ng/ml)8111.431.621.638472.374.443.538732.362.422.748981.321.241.669206.039.229289283.804.693.999526.769533.771.281.1310551.421.281.1312130.971.191.0712454.116.46

Table 3: Non-MI Patients with High ST2 Levels

[0075] These results demonstrate that the presence of elevated ST2 (e.g., above 0.2 ng/ml) in patients with chest 50 pain who are troponin negative is associated with a high probability of pulmonary disease.

OTHER EMBODIMENTS

55

[0076] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. [0077] The invention is further described in the following clauses:

1. A kit for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject, the kit comprising (i) one or both of a binding composition that specifically binds to IL-33 and a binding composition that specifically binds to a biomarker for CVD, and (iii) instructions for use in a method of determining the likelihood of the presence of CVD or PD in a subject, the method comprising:

- 5 method comprisi
 - determining a level of one or both of IL-33 and ST2 in a sample from a subject; determining a level of a biomarker for CVD in the sample; and comparing the level of IL-33 or ST-2, and the level of the CVD biomarker, in the sample to preselected corresponding reference levels;
 - wherein the levels in the sample as compared to the reference levels is correlated with the likelihood of the presence of CVD or PD.
- ¹⁵ 2. The kit of clause 1, wherein the IL-33 and/or ST2 and the CVD biomarker comprise polypeptides, and the binding composition comprises an antibody or antigen binding fragment thereof that binds specifically to the polypeptides.

3. The kit of clause 1, wherein the IL-33 and/or ST2 and the CVD biomarker comprise nucleic acids and the binding composition comprises a probe that binds specifically to nucleic acid.

20

10

4. The kit of any of clauses 1 to 3, wherein the CVD biomarker is a natriuretic peptide selected from the group consisting of brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP.

5. A method of determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject, the method comprising:

determining a level of a first biomarker selected from the group consisting of IL-33 and ST2 in a sample from a subject;

- determining a level of a second biomarker for CVD in the sample; and
 comparing the level of the first biomarker and second CVD biomarker in the sample to preselected corresponding reference levels;
- wherein the levels of the biomarkers in the sample as compared to the reference levels is correlated with the likelihood of the presence of CVD or PD.
 - 6. The method of clause 5, wherein the subject has chest pain or dyspnea.
- 7. The method of clause 5, wherein the CVD biomarker is a natriuretic peptide selected from the group consisting
 of brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-terminal proBNP (NT-proBNP), atrial natriuretic
 peptide (ANP), proANP, or NT-proANP.

8. The method of clause 5, wherein determining a level of IL-33 in the sample comprises determining a level of one, two, or all three of mature IL-33, pre-IL-33, and pro-IL-33.

45

9. The method of clause 5, wherein the sample comprises blood, serum, plasma, urine, or body tissue.

10. The method of clause 5, wherein the reference levels represent a level in a subject who has a high likelihood of having pulmonary disease.

50

11. The method of clause 5, wherein the reference levels represent a level in a subject who has a high likelihood of having cardiovascular disease.

12. The method of clause 5, wherein the reference levels represent a level in a subject with a known severity of cardiovascular or pulmonary disease.

13. The method of clause 5, wherein determining a level of a biomarker in the sample comprises contacting a binding composition to the sample, wherein the binding composition specifically binds to the biomarker, and measuring or

determining the specific binding of the binding composition to the sample.

14. The method of clause 13, wherein the binding composition comprises an antibody that binds specifically to a biomarker comprising a polypeptide.

5

15

15. The method of clause 13, wherein the binding composition comprises an oligonucleotide probe that bind specifically to a biomarker comprising a polynucleotide.

16. The kit of any of clauses 1-3 or the method of clause 5, wherein the CVD is acute coronary syndrome (ACS),
 myocardial infarction , heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pericarditis, endo-carditis, or stroke.

17. The kit of any of clauses 1-3 or the method of clause 5, wherein the PD is chronic obstructive pulmonary disease (COPD), asthma, pneumonia, pneumothorax, pulmonary embolism, pleural effusion, metastatic disease, pulmonary edema, gastrooesophageal reflux disease with aspiration, pulmonary embolism, and restrictive lung disease.

18. The method of clause 5, further comprising determining a level in the sample of each of one or more other biomarkers.

20 19. The method of clause 18, wherein the one or more other biomarkers are selected from the group consisting of troponin, creatine kinase MB (CK-MB), ischemia-modified albumin (IMA), Interleukin-6 (IL-6), C-reactive protein (CRP), creatinine, D-dimers, blood urea nitrogen (BUN), liver function enzymes, albumin, and bacterial endotoxin.

25 Claims

30

- 1. An in vitro method for selecting a treatment for a subject having chest pain or dyspnea, the method comprising:
 - (a) determining a level of soluble ST2 (Interleukin 1 Receptor Like 1 (IL1RL1)) in a sample from a subject having chest pain or dyspnea;
 - (b) determining a level of brain natriuretic peptide (BNP) in the sample;

(c) comparing the level of soluble ST2 in the sample to a reference level of soluble ST2 in a subject who has neither cardiovascular disease (CVD) nor pulmonary disease (PD), has a high likelihood of having PD or CVD, or has CVD and/or PD;

³⁵ (d) comparing the level of BNP in the sample to a low threshold level of BNP of 100 pg/mL and a high threshold level of BNP of 500 pg/mL; and

(e) identifying a subject having chest pain or dyspnea, a soluble ST2 level less than the reference level of soluble ST2, and a BNP level equal to or greater than 100 pg/mL as having CVD, and selecting for the subject a treatment for CVD;

40 identifying a subject having chest pain or dyspnea, a soluble ST2 level equal to or greater than the reference level of soluble ST2, and a BNP level that is equal to or less than 500 pg/mL as having PD, and selecting for the subject a treatment for PD; or

identifying a subject having chest pain or dyspnea, a soluble ST2 level equal to or greater than the reference level of soluble ST2, and a BNP level greater than 500 pg/mL as having CVD, and selecting for the subject a treatment for CVD.

- 2. The method of claim 1, wherein the method comprises identifying a subject having chest pain or dyspnea, a soluble ST2 level less than the reference level of soluble ST2, and a BNP level equal to or greater than 100 pg/mL as having CVD, and selecting for the subject a treatment for CVD.
- 50

45

- 3. The method of claim 1, wherein the method comprises identifying a subject having chest pain or dyspnea, a soluble ST2 level equal to or greater than the reference level of soluble ST2, and a BNP level that is equal to or less than 500 pg/mL as having PD, and selecting for the subject a treatment for PD.
- 55 4. The method of claim 1, wherein the method comprises identifying a subject having chest pain or dyspnea, a soluble ST2 level equal to or greater than the reference level of soluble ST2, and a BNP level greater than 500 pg/mL as having CVD, and selecting for the subject a treatment for CVD.

- 5. The method of any one of claims 1-4, wherein the subject has chest pain.
- 6. The method of any one of claims 1-4, wherein the subject has dyspnea.
- The method of any one of claims 1-6, wherein the level of soluble ST2 is determined at 2, 4, 6, 8, 12, 18, or 24 hours, or 1-7 days after the onset of symptoms in the subject.
 - 8. The method of any one of claims 1-7, wherein the sample comprises blood, serum, or plasma.
- 10 9. The method of any one of claims 1-8, wherein determining a level of soluble ST2 or the level of BNP in the sample comprises contacting a binding composition to the sample, wherein the binding composition specifically binds to soluble ST2 or BNP, and measuring or determining the specific binding of the binding composition to the sample.
 - **10.** The method of claim 9, wherein the binding composition comprises an antibody that binds specifically to soluble ST2 or BNP.
 - **11.** The method of claim 10, wherein the antibody is coupled to a fluorescent material.
- 12. The method of any one of claims 1-11, wherein the CVD is acute coronary artery syndrome (ACS), myocardial infarction, heart failure, angina, cardiac hypertrophy, myocarditis, pericarditis, endocarditis, or stroke.
 - **13.** The method of any one of claims 1-11, wherein the PD is chronic obstructive pulmonary disease (COPD), asthma, pneumonia, pneumothorax, pleural effusion, metastatic disease, pulmonary edema, pulmonary embolism, or restrictive lung disease.

25

30

15

- **14.** The method of any one of claims 1-13, further comprise determining a level in the sample of one or more other biomarkers.
- **15.** The method of claim 14, wherein the one or more other biomarkers are selected from the group consisting of: creatine kinase MB (CK-MB), C-reactive protein (CRP), creatinine, and D-dimers.

35

40

45

50

55

Figure 1

		ST2 not HF Not COPD	ST2 not HF COPD	st2 not HF	ST2 HF not COPD	ST2 HF COPD	ST2 CHF
N	Valid	224	161	385	155	53	208
	Missing	375	438	214	444	546	391
Median		.1220	.2305	.1448	.4944	.6532	.5033
Percentiles	25	.0502	.0823	,0622	.2393	.2819	.2671
·	75	.2232	.6555	.4227	1.1287	1.9560	1.2254
			.001	P<0.001	*		

Statistics




Figure 2



5

EUROPEAN SEARCH REPORT

Application Number EP 15 16 3587

		DOCUMENTS CONSID	ERED TO BE RELEVANT		
	Category	Citation of document with in of relevant passa	dication, where appropriate, ges	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
10	A	US 2004/121343 A1 (ET AL) 24 June 2004 * paragraph [0086] claims 1-12; exampl * paragraph [0223]	1-15	INV. G01N33/53 G01N33/543 C07K14/54 C07K14/58	
15	A	serum soluble ST2 r heart failure bioma CIRCULATION, LIPPIN	rker",	1-15	
20		WILKINS, US, vol. 107, no. 5, 1 February 2003 (20 721-726, XP00298543 ISSN: 0009-7322 * abstract *			
25		* page 722, left-ha *	nd column, paragraph 2 and column, paragraph 2		
	A	US 2004/048286 A1 (LEE RICHARD T [US])			TECHNICAL FIELDS SEARCHED (IPC)
30		11 March 2004 (2004 * paragraph [0263];	1-15	G01N	
35	A	OSHIKAWA KATSUHISA soluble ST2 protein patients with asthm exacerbation", AMERICAN JOURNAL OF CRITICAL CARE MEDIC	levels in sera of a with an acute RESPIRATORY AND INE,	1-15	
40		, pages 277-281, XP ISSN: 1073-449X	July 2001 (2001-07-15) 002552703, and column, paragraph 4 		
45					
2		The present search report has b	•		
50		Place of search The Hague	Date of completion of the search 1 February 2016	Wie	Examiner Sner, Martina
50 (100000000000000000000000000000000000	X : part Y : part doct	ATEGORY OF CITED DOCUMENTS icoularly relevant if taken alone ticularly relevant if combined with anoth ument of the same category	T : theory or principle E : earlier patent doc after the filing date	underlying the in ument, but publis o the application	nvention
55 OG	A : tech O : nor P : inte	nnological background n-written disclosure rmediate document	& : member of the sa document		, corresponding

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 15 16 3587

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

01-02-2016

10	Patent document cited in search report	Publication date	Patent family member(s)	Publication date
15	US 2004121343 A	1 24-06-2004	CA 2692217 A1 CN 1751128 A JP 2009103721 A US 2004121343 A1	15-07-2004 22-03-2006 14-05-2009 24-06-2004
20	US 2004048286 A	1 11-03-2004	AT 534747 T AU 2003234407 A1 CA 2484897 A1 CN 1668763 A CN 102533972 A DK 1532269 T3	15-12-2011 11-11-2003 20-11-2003 14-09-2005 04-07-2012 12-03-2012
25			EP 1532269 A2 EP 2336359 A1 ES 2375181 T3 JP 4514606 B2 JP 5094793 B2 JP 2005538700 A JP 2010041998 A	25-05-2005 22-06-2011 27-02-2012 28-07-2010 12-12-2012 22-12-2005 25-02-2010
30			PT 1532269 E US 2004048286 A1 US 2006216755 A1 US 2010159607 A1 US 2011250703 A1 US 2013251664 A1	17-01-2012 11-03-2004 28-09-2006 24-06-2010 13-10-2011 26-09-2013
35			US 2013273562 A1 US 2015153360 A1 WO 03094856 A2	17-10-2013 04-06-2015 20-11-2003
40				
45				
50	M Po459			
55	ਿ ਅਸਾਰ ਪੁੱਧ ਜੂੰ ਸਿੰਗ ਸਿੰਗ ਸਿੰਗ ਸਿੰਗ ਸਿੰਗ ਸਿੰਗ ਸਿੰਗ ਸਿੰ	e Official Journal of the Eurc	pean Patent Office, No. 12/82	

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6176962 B [0036]
- US 6517234 B [0036]
- US 20030124624 A [0044]
- US 20040048286 A [0044] [0056]

Non-patent literature cited in the description

- Current Protocols in Molecular Biology. John Wiley & Sons, 1989, 6.3.1-6.3.6 [0034]
- LE DOUSSAL et al. New Engl. J. Med., 1991, vol. 146, 169-175 [0036]
- GIBELLINI et al. J. Immunol., 1998, vol. 160, 3891-3898 [0036]
- HSING ; BISHOP. New Engl. J. Med., 1999, vol. 162, 2804-2811 [0036]
- EVERTS et al. New Engl. J. Med., 2002, vol. 168, 883-889 [0036]
- MANIATIS et al. Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1982 [0037]
- SAMBROOK ; RUSSELL. Molecular Cloning. Cold Spring Harbor Laboratory Press, 2001 [0037]
- WU. Recombinant DNA. Academic Press, vol. 217 [0037]
- AUSBEL et al. Current Protocols in Molecular Biology. John Wiley and Sons, Inc, 2001, vol. 1-4 [0037]
- KIESER et al. FEBS Lett., 1995, vol. 372 (2-3), 189-93 [0040]
- KUMAR et al. J. Biol. Chem., 1995, vol. 270 (46), 27905-13 [0040]
- YANAGISAWA et al. FEBS Lett., 1992, vol. 302 (1), 51-3 [0040]
- KUROIWA et al. *Hybridoma*, 2000, vol. 19 (2), 151-9 [0040]

- US 20050130136 A [0044] [0056]
- US 20050250156 A [0044]
- US 20050203046 A [0049] [0052] [0069]
- WEINBERG et al. Circulation, 2002, vol. 106 (23), 2961-6 [0040]
- WEINBERG et al. Circulation, 2003, vol. 107 (5), 721-6 [0040]
- SHIMPO et al. Circulation, 2004, vol. 109 (18), 2186-90 [0040]
- LOHNING et al. Proc. Natl. Acad. Sci. U. S. A., 1998, vol. 95 (12), 6930-5 [0041]
- SCHMITZ et al. Immunity, 2005, vol. 23 (5), 479-90
 [0041] [0049] [0052]
- BRINT et al. Nat. Immunol., 2004, vol. 5 (4), 373-9
 [0041]
- BRUNEAU et al. Cardiovasc. Res., 1994, vol. 28 (10), 1519-25 [0041]
- TOMINAGA. FEBS Lett., 1989, vol. 258, 301-304 [0042]
- TOMINAGA et al. Biochim. Biophys. Acta, 1992, vol. 1171, 215-218 [0042]
- BAEKKEVOLD et al. Am. J. Path., 2003, vol. 163, 69-79 [0051]
- MEHRA et al. J Am Coll Cardiol., 2004, vol. 43 (9), 1590-1595 [0055]
- SILVER et al. Cong. Heart Fail., 2004, vol. 10 (5), 1-30 [0055]
- DHALLA et al. Mol. Cell Biochem., 1989, vol. 87, 85-92 [0056]
- MOE et al. Am. Heart J., 2000, vol. 139, 587-95 [0056]

patsnap

公开(公告)号	EP2995951A1	公开(公告)日	2016-03-16				
申请号	EP2015163587	申请日	2007-05-02				
[标]申请(专利权)人(译)	重症监护诊断股份有限公司						
申请(专利权)人(译)	急救诊断,INC.						
当前申请(专利权)人(译)	急救诊断,INC.						
[标]发明人	SNIDER JAMES V JACOBSON SVEN						
发明人	SNIDER, JAMES V. JACOBSON, SVEN						
IPC分类号	G01N33/53 G01N33/543 C07K14/	G01N33/53 G01N33/543 C07K14/54 C07K14/58					
CPC分类号		C07K14/54 C07K14/58 C07K14/7155 G01N33/6869 G01N33/74 G01N2333/58 G01N2800/12 G01N2800/32 Y10T436/143333 C12Q1/6883 G01N33/53 G01N33/6893					
代理机构(译)	WILLIAMS,加雷思·欧文						
优先权	60/797285 2006-05-02 US PCT/US2007/068024 2007-05-02	WO					
其他公开文献	EP2995951B1						
外部链接	Espacenet						

摘要(译)

描述了使用ST2 /白细胞介素1受体1(IL1RL1)和/或白细胞介素33(IL-33)确定受试者中存在心血管疾病(CVD)或肺病(PD)的可能性的方 法和试剂盒,以及用于CVD的生物标志物,例如利尿钠肽,例如脑利尿 钠肽(BNP),激素原BNP(proBNP),N-末端proBNP(NTproBNP),心房利钠肽(ANP),proANP或NT-proANP。 Figure 1

			Statis	stics			
		ST2 not HF Not COPD	ST2 not HF ÇOPD	st2 hot HF	ST2 HF not COPD	ST2 HF COPD	ST2 CHF
Ŋ	Valid	224	161	385	155	53	208
	Missing	375	438	214	444	546	391
Median		.1220	.2305	.1448	,4944	.5532	.5033
Percentiles	25	.0502	.0823	.0622	.2393	.2819	.2671
	75	.2232	.6555	,4227	1,1287	1.9560	1.2254
		P<0	.001	P<1.001	P=Q	.10	